Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
The Infinity™ DBS system with directional leads is intended to deliver stimulation to target areas in the brain to aid in the treatment of movement disorders, Parkinson disease, and essential tremor. With this approval, the system is now indicated to target the subthalamic nucleus, ventral intermediate nucleus, and internal globus pallidus.
“The internal segment of the global pallidus, or GPi, is a well-established valuable DBS target for the management of the motor signs associated with Parkinson disease, and is a preferred target for many patients, particularly for those with troublesome medication induced dyskinesia,” said Jerrold Vitek, MD, PhD, head of the Neurology Department, director of the Neuromodulation Research Program, and center director of the University of Minnesota Udall Center of Excellence for Parkinson’s Research.
Clinicians are able to manage therapy through an Apple iPad mini, using Abbott’s Informity™ Programming feature, allowing them to direct stimulation for optimal therapeutic outcomes. In addition, as new advancements are approved, the implanted system can be wirelessly upgraded and does not require recharging. Patients have the ability to adjust their settings with the Infinity DBS System iPod touch controller.
“Abbott’s PROGRESS study has led the way in establishing the value of directional DBS systems for targeted areas of the brain,” said Binith Cheeran, MD, director of medical affairs, deep brain stimulation, a part of Abbott’s neuromodulation business. “The ability to optimize the programming for each individual opens the door for a new standard of care for DBS therapy.”
For more information visit abbott.
